Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266494 · ClinicalTrials.gov registry record · Phase 4
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
A Phase 4 study of Frostbite, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06266494 is a Phase 4 study of Frostbite that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06266494, a Phase 4 study of Frostbite, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the effectiveness of two different treatments for preventing infection from frostbite injuries. These two treatments are A) aloe vera and B) long-acting silver wound dressings. The investigators will also study the safety and effectiveness of Dalbavancin, an FDA approved antibiotic used for treating people who develop frostbite wound infections, as well as evaluate how frostbite damage to individuals' bodies may affect how fast their kidney clear drugs from their systems.
Conditions Studied
Interventions
- DRUG Dalbavancin
- DEVICE Long-Acting silver dressings
- OTHER Aloe Vera
Study Locations (1)
Colorado
- University of Colorado Denver Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06266494
The ClinicalTrials.gov registry entry for NCT06266494 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Frostbite appearing as the primary indexed condition, and to 3 interventions - of which Dalbavancin is the first listed.
NCT06266494 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06266494 about?
NCT06266494 is a clinical study titled "Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis". This study will compare the effectiveness of two different treatments for preventing infection from frostbite injuries. These two treatments are A) aloe vera and B) long-acting silver wound dressings. The investigators will also study the safety and effectiveness of Dalbavancin, an FDA approved anti...
What is the current status of trial NCT06266494?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-03-01. Estimated completion is 2026-08.
What conditions does trial NCT06266494 study?
This clinical trial studies the following conditions: Frostbite.
What interventions are being tested in trial NCT06266494?
The interventions under investigation include: Dalbavancin (DRUG), Long-Acting silver dressings (DEVICE), Aloe Vera (OTHER).
Who is sponsoring clinical trial NCT06266494?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06266494 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frostbite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.